Clinical trial: renzapride therapy for constipation‐predominant irritable bowel syndrome – multicentre, randomized, placebo‐controlled, double‐blind study in primary healthcare setting

Abstract

This study confirms the gastrointestinal prokinetic effects of renzparide. The data also suggested a potentially beneficial effect on abdominal pain/discomfort in women with constipation-predominant irritable bowel syndrome.